$EVMN · Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
More about this company
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-02-19 | SCHEDULE 13D/A | LSP 7 Cooperative UA | 14.7% | Med | filing |
| 2026-02-17 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 9.7% | Med | filing |